A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children Age 7 Years Through 18 Years

Trial Profile

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children Age 7 Years Through 18 Years

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs MEDI 3250 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Sep 2015 According to a Daiichi Sankyo media release, data from this will support regulatory submission in Japan.
    • 13 May 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 05 Feb 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top